We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

31 hedge funds and large institutions have $5.42M invested in Acorda Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

950% more call options, than puts

Call options by funds: $63K | Put options by funds: $6K

3% less funds holding

Funds holding: 32 → 31 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

43% less capital invested

Capital invested by funds: $9.48M → $5.42M (-$4.06M)

78% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 9

Holders
31
Holders Change
-1
Holders Change %
-3.13%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
9
Closed
5
Calls
$63K
Puts
$6K
Net Calls
+$57K
Net Calls Change
+$81K

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$26.5K
2
UBS Group
UBS Group
Switzerland
+$5.51K
3
Citigroup
Citigroup
New York
+$3.26K
4
TRCT
Tower Research Capital (TRC)
New York
+$1.14K
5
Northern Trust
Northern Trust
Illinois
+$983

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$674K
2
Federated Hermes
Federated Hermes
Pennsylvania
-$193K
3
Invesco
Invesco
Georgia
-$186K
4
Millennium Management
Millennium Management
New York
-$98.4K
5
Bank of America
Bank of America
North Carolina
-$59.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.14M -$13.6K -347 -1%
CCA
2
Canyon Capital Advisors
Texas
$1.04M – – –
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$751K – – –
Point72 Asset Management
4
Point72 Asset Management
Connecticut
$747K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$549K – – –
BCM
6
Bridgeway Capital Management
Texas
$393K – – –
BlackRock
7
BlackRock
New York
$266K -$2.36K -60 -0.7%
Wells Fargo
8
Wells Fargo
California
$80K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$75K – – –
Millennium Management
10
Millennium Management
New York
$66K -$98.4K -2,502 -55%
State Street
11
State Street
Massachusetts
$51K – – –
UAS
12
United Asset Strategies
New York
$44K – – –
Northern Trust
13
Northern Trust
Illinois
$43K +$983 +25 +2%
SFI
14
Susquehanna Fundamental Investments
Pennsylvania
$36K – – –
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$32K -$48.6K -1,237 -56%
SC
16
Saltoro Capital
Texas
$24K – – –
Two Sigma Advisers
17
Two Sigma Advisers
New York
$23K -$5.7K -145 -17%
Jane Street
18
Jane Street
New York
$22K +$26.5K +675 New
Simplex Trading
19
Simplex Trading
Illinois
$9K -$7.28K -185 -39%
Russell Investments Group
20
Russell Investments Group
United Kingdom
$9K – – –
Morgan Stanley
21
Morgan Stanley
New York
$8K -$511 -13 -5%
UBS Group
22
UBS Group
Switzerland
$4K +$5.51K +140 +14,000%
Citigroup
23
Citigroup
New York
$3K +$3.26K +83 New
Federated Hermes
24
Federated Hermes
Pennsylvania
$1K -$193K -4,901 -99%
TRCT
25
Tower Research Capital (TRC)
New York
$1K +$1.14K +29 New
1
2

ACOR Hedge Fund Activity: Q1 2022 in Review

31 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2022, worth a combined $5.42M — down 43% from $9.48M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ACOR and 4 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 2 added.

The largest buyer was Jane Street, opening a new position worth an estimated $26.5K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $674K sold.

  • 31 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2022, down from 32 in Q4 2021.
  • Funds reported $5.42M of Acorda Therapeutics stock for Q1 2022, down 43% quarter-over-quarter.
  • 4 funds opened new Acorda Therapeutics positions in Q1 2022 and 5 closed out, a net change of -1 holder.
  • The largest Acorda Therapeutics buyer in Q1 2022 was Jane Street, an estimated $26.5K added.
  • The largest Acorda Therapeutics seller in Q1 2022 was Highbridge Capital Management, an estimated $674K sold.

Based on aggregated 13F filings for Q1 2022.